BioXcel Therapeutics Announces FDA Acceptance of IND for Lead Immuno-oncology Candidate, BXCL701, in Treatment Emergent Neuroendocrine Prostate Cancer
05 nov. 2018 04h00 HE
|
BioXcel Therapeutics, Inc.
First-in-human Phase 1b / 2 combination trial of BXCL701 and pembrolizumab (Keytruda®) expected to initiate in 4Q 2018 Efficacy study with objective response rate endpoint to enroll up to 40 patients...
BioXcel Therapeutics to Host Third Quarter 2018 Financial Results and Business Update Conference Call
02 nov. 2018 06h00 HE
|
BioXcel Therapeutics, Inc.
Conference call scheduled for November 09, 2018 at 8:00 AM ET NEW HAVEN, Conn., Nov. 02, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage...
BioXcel Therapeutics Announces Presentation on Functional Immunological Memory Formation Across Diverse Tumor Types at the SITC 2018 Annual Meeting
31 oct. 2018 04h00 HE
|
BioXcel Therapeutics, Inc.
Data underscores the potential of triple combination of BXCL701, NKTR-214 and an anti-PD1 agent as an anti-cancer therapy NEW HAVEN, Conn., Oct. 31, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics,...
BioXcel Therapeutics Provides Update on the Clinical Advancement of BXCL501 for the Acute Treatment of Agitation
30 oct. 2018 04h00 HE
|
BioXcel Therapeutics, Inc.
On track to initiate BXCL501 first-in-human pharmacokinetic (bioavailability) and safety study Data readout expected first half 2019 NEW HAVEN, Conn., Oct. 30, 2018 (GLOBE NEWSWIRE) -- BioXcel...
BioXcel Therapeutics to Present at the 2018 BIO Investor Forum
11 oct. 2018 16h01 HE
|
BioXcel Therapeutics, Inc.
NEW HAVEN, Conn., Oct. 11, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence...
BioXcel Therapeutics Announces Submission of IND for Lead Immuno-oncology Candidate, BXCL701, in Treatment Emergent Neuroendocrine Prostate Cancer
08 oct. 2018 07h00 HE
|
BioXcel Therapeutics, Inc.
NEW HAVEN, Conn., Oct. 08, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence...
BioXcel Therapeutics Expands Immuno-Oncology Partnership with Nektar into Clinical Development in Pancreatic Cancer
24 sept. 2018 07h00 HE
|
BioXcel Therapeutics, Inc.
NEW HAVEN, Conn., Sept. 24, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence...
BioXcel Therapeutics Enhances Leadership with Appointment of Chetan D. Lathia, Ph.D. as Senior Vice President, and Head of Translational Medicine, Clinical Pharmacology and Regulatory Affairs
18 sept. 2018 08h00 HE
|
BioXcel Therapeutics, Inc.
NEW HAVEN, Conn., Sept. 18, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence...
BioXcel Therapeutics Appoints Dr. David C. Hanley as Vice President and Head of Global Pharmaceutical Development and Operations
04 sept. 2018 08h00 HE
|
BioXcel Therapeutics, Inc.
BRANFORD, Conn., Sept. 04, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence...
BioXcel Therapeutics to Present at the 20th Annual HC Wainwright Global Investment Conference
28 août 2018 08h00 HE
|
BioXcel Therapeutics, Inc.
NEW HAVEN, Conn., Aug. 28, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence...